NASDAQ:PALI

Palisade Bio Q1 2026 Earnings Results & Report

Palisade Bio logo
$0.84 -0.09 (-9.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.02 (+2.39%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio missed analyst earnings expectations in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.05 versus the -$0.04 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Palisade Bio EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Palisade Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Palisade Bio Q1 2026 Earnings FAQ

Palisade Bio (NASDAQ:PALI) reported earnings of -$0.05 per share for Q1 2026, missing the consensus estimate of -$0.04. The report was announced on Tuesday, May 12, 2026.

Palisade Bio Earnings Headlines

FY2026 EPS Estimate for Palisade Bio Reduced by Analyst
FY2026 EPS Forecast for Palisade Bio Reduced by Analyst
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Palisade Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email.

About Palisade Bio

Palisade Bio (NASDAQ:PALI) is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions.

Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Palisade Bio’s candidates are in clinical development and are not approved for commercial use.

View Palisade Bio Profile